AU2003229627A1 - Ve-ptp as regulator of ve-cadherin mediated processes or disorders - Google Patents

Ve-ptp as regulator of ve-cadherin mediated processes or disorders

Info

Publication number
AU2003229627A1
AU2003229627A1 AU2003229627A AU2003229627A AU2003229627A1 AU 2003229627 A1 AU2003229627 A1 AU 2003229627A1 AU 2003229627 A AU2003229627 A AU 2003229627A AU 2003229627 A AU2003229627 A AU 2003229627A AU 2003229627 A1 AU2003229627 A1 AU 2003229627A1
Authority
AU
Australia
Prior art keywords
ptp
disorders
regulator
mediated processes
cadherin mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003229627A
Inventor
Urban Deutsch
Matthew Golding
Roman Nawroth
David T. Shima
Dietmar Vestweber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of AU2003229627A1 publication Critical patent/AU2003229627A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2003229627A 2002-04-08 2003-04-08 Ve-ptp as regulator of ve-cadherin mediated processes or disorders Abandoned AU2003229627A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02007837.4 2002-04-08
EP02007837 2002-04-08
PCT/EP2003/003645 WO2003084565A2 (en) 2002-04-08 2003-04-08 Ve-ptp as regulator of ve-cadherin mediated processes or disorders

Publications (1)

Publication Number Publication Date
AU2003229627A1 true AU2003229627A1 (en) 2003-10-20

Family

ID=28685843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003229627A Abandoned AU2003229627A1 (en) 2002-04-08 2003-04-08 Ve-ptp as regulator of ve-cadherin mediated processes or disorders

Country Status (2)

Country Link
AU (1) AU2003229627A1 (en)
WO (1) WO2003084565A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055416A2 (en) * 2004-11-15 2006-05-26 Eyetech Pharmaceuticals, Inc. Transgenic mouse capable of over-expressing vascular endothelial protein tyrosine phosphatase (ve-ptp)
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6483148B2 (en) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド HPTP-β inhibitor
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
CN113713101B (en) 2015-09-23 2023-07-28 视点制药公司 Methods of treating intraocular pressure with TIE-2 activators
JP7564824B2 (en) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド Tie-2 activator targeting Schlemm's canal

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604731D0 (en) * 1996-12-20 1996-12-20 Tamas Bartfai Konsulting Ab A component of intercellular junctions in the endothelium
EP1046715A1 (en) * 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2

Also Published As

Publication number Publication date
WO2003084565A3 (en) 2004-03-25
WO2003084565A2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
AU2003274342A1 (en) Compositions for the treatment of autoimmune disorders
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2003261405A1 (en) Regulation of transcription elongation factors
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
AU2003236991A1 (en) Representations of processes
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU2002334321A1 (en) Method for the production of phytoalexins
AU2003206803A1 (en) Production of alkenones
AU2003293099A1 (en) Treatment of dna damage related disorders
AU2003229627A1 (en) Ve-ptp as regulator of ve-cadherin mediated processes or disorders
AU2003233358A1 (en) Method of viewing and controlling balance of the vertebral column
AU2003293895A1 (en) Method for the production of isocyanates
AU2002952155A0 (en) Production of titania
AU2003248990A1 (en) Method of controlling scale formation
AU2003275505A1 (en) Electowinning of metals
AU2003206367A1 (en) Technical field of the invention
AU2003292784A1 (en) Method of refining metal surface and metal product by the method
AU2003238443A1 (en) Separation of molecules
AU2003250329A1 (en) Regulation of novel human asparagine-hydroxylases
AU2003259689A1 (en) 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2002361488A1 (en) Field and background of the invention
AU2003278748A1 (en) Chemotherapy method using-rays background of the invention
AU2003266271A1 (en) Regulation of human esterase
AU2003245879A1 (en) Method for the production of substituted trifluoroetylenes
AU2003238034A1 (en) Novel use of imidazotriazinones

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase